Across TCGA pan-cancer cohorts, ZNF616 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF616 data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ZNF616 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF616 expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

UCEC, KIRP, and PRAD are the cancer types where ZNF616 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.906	0.424	.006	24	view →
KIRP	OS	Median	All	0.121	0.692	<.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	DFS	Median	IV	1.000	0.324	.044	1	view →
SKCM	DFS	Median	II,III,IV	0.884	0.560	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ZNF616 tumor-vs-normal RNA expression · all ZNF616 data types